Pulmonary bacterial agents and antibiotic therapy in patients with cystic fibrosis: guide for the medical personnel;Agentes bacterianos pulmonares y terapia antibiótica en pacientes con fibrosis quística: Guía para el personal sanitario

Archivos de Medicina

Volumn 5, Issue 2, 2009, Pages

  Coutinho, Henrique Douglas M ^a   Falcão Silva, Vivyanne S ^b   Gonçalves, Gregório Fernandes ^b  

^a Laboratorio de Investigación de Productos Naturales   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL INFECTION; CYSTIC FIBROSIS; HUMAN; LUNG INFECTION; MEDICAL PERSONNEL; PRACTICE GUIDELINE;

EID: 70350215653     PISSN: 16989465     EISSN: None     Source Type: Journal    
DOI: 10.3823/028     Document Type: Article

References (85)

1. Chu KK, Davidson DJ, Halsey TK, Chung JW, Speert DP: Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun 2002, 70:2715-2720.
2. Goldman L, Bennett JC: CECIL: Textbook of Medicine. 21st edition. Guanabara Koogan, Rio de Janeiro; 2001.
3. Chaparro C, Maurer J, Gutierrez C, Krajden M, Chan C, Winton T, Keshavjee S, Scavuzzo M, Tullis E, Hutcheon M, Kesten S: Infection with Burkholderia cepacia in cystic fibrosis: Outcome following lung transplantation. Am J Respir Crit Care Med 2001, 163:43-48.
4. Boucher RC: New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004, 23:146-158.
5. Accurso FJ: Update in cystic fibrosis 2005. Am J Respir Crit Care Med 2006, 173:944-947.
6. Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, Abele-Horn M: Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008, 7(2):123-127.
7. Cullen AR, Cannon CL, Mark EJ, Colin AA: Mycobacterium abscessus Infection in Cystic Fibrosis Colonization or Infection? Am J Respir Crit Care Med 2000, 161:641-645.
8. Oliver A, Maiz L, Canton R, Escobar H, Baquero F, Gómez-Mampaso E: Nontuberculous mycobacteria in pacients with cystic fibrosis. Clin Infec Dis 2001, 32:1298-1303.
9. Oliver KN, Weber DJ, Wallace RJ, Escobar H, Baquero F, Gómez-Mampaso E: NMntuberculous mycobacteria I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167:828-34.
10. Sermet-Gaudelus I, Le Bourgeois ML, Pierre-Audigier C, Offredo C, Guillemot D, Halley S, Akoua-Koffi C, Vincent V, Sivadon-Tardy V, Ferroni A, Berche P, Scheinmann P, Lenoir G, Gaillard JL: Mycobacterium abscessus and Children with Cystic Fibrosis. Emerg Infect Dis 2003, 9:1587-1591.
11. Jönsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Olsson C: Molecular Epidemiology of Mycobacterium abscessus, with Focus on Cystic Fibrosis. J Clin Microbiol 2007, 45:1497-1504.
12. Le Burgeois M, Sermet-Gaudelus I, Catherinot E, Gaillard JL: Mycobactéries atypiques et mucoviscidose. Archiv Pediatr 2005, 12(Suppl 2):S117-S121.
13. Saiman L, Siegel J: Infection control in Cystic Fibrosis. Clin Microbiol Rev 2004, 17:57-71.
14. Lyczak JB, Cannon CL, Pier GB: Lung Infections Associated with Cystic Fibrosis. Clin Microbiol Rev 2002, 15:94-222.
15. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW: Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis. J Pediatr in press. doi:10.1016/j.jpeds.2008.08.001.
16. Goerke C, Kraning K, Stern M, Döring G, Botzenhart K, Wolz C: Molecular epidemiology of community-acquired Staphylococcus aureus in families with and without cystic fribrosis patients. J Infect Dis 2000, 181:984-989.
17. Branger C, Gardye C, Lambert-Zechovsky N: Persistence of Staphylococcus aureus strains among cystic fibrosis patients over extended periods of time. J Med Microbiolol 1996, 45:294-301.
18. Spicuzza L, Sciuto C, Vitaliti G, Di Dio G, Leonardi S, La Rosa M: Emerging pathogens in cystic fibrosis: Ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis in press. DOI 10.1007/s10096-008-0605-4
19. Campana S, Taccetti G, Ravenni N, Masi I, Audino S, Sisi B, Repetto T, Döring G, Martino M: Molecular epidemiology of Pseudomonas aeruginosa, Burkholderia cepacia complex and methicillin-resistant Staphylococcus aureus in a cystic fibrosis center. J Cyst Fibros 2004, 3:159-163.
20. Yang JA, Park DW, Sohn JW: Novel PCR-restriction fragment length polymorphism analysis for rapid typing of staphylococcal cassette chromosome mec elements. J Clin Microbiol 2006, 44:236-238.
21. Tristan A, Bes M, Meugnier H: Global distribution of Panton-Valentine leukocidin-positive methicillin-resistant Staphylococcus aureus. Emerg Infect Dis 2007, 13:594-600.
22. Kahl B, Herrmann M, Everding AS, Koch HG, Becker K, Harms E, Proctor RA, Peters G: Persistent infection with small colony variant strains of Staphylococcus aureus in patients with cystic fibrosis. J Infect Dis 1998, 177:1023-1029.
23. Vergison A, Denis O, Deplano A, Casimir G, Claeys G, DeBaets F, DeBoeck K, Douat N, Franckx H, Gigi J, Ieven M, Knoop C, Lebeque P, Lebrun F, Malfroot A, Paucquay F, Pierard D, Van Eldere J, Struelens MJ: National survey of molecular epidemiology of Staphylococcus aureus colonization in Belgian cystic fibrosis patients. J Antimicrob Chemother 2007, 59:893-999.
24. Sadowska B, Bonar A, von Eiff C, Proctor RA, Chmiela M, Rudnicka W, Rózalska B: Characteristics of Staphylococcus aureus, isolated from airways of cystic fibrosis patients, and their small colony variants. FEMS Immunol Med Microbiol 2002, 32:191-197.
25. Hart CA, Winstanley C: Persistent and aggressive bacteria in the lungs of cystic fibrosis children. Br Med Bull 2002, 61:81-96.
26. Vornberg RP, Gastmeier P: Isolation of Infectious Cystic Fibrosis Patients: Results Of A Systematic Review. Infect Control Hosp Epidemiol 2005, 26:401-409.
27. Tramper-Stranders GA, Ent CK van der, Slieker MG, Terheggen-Lagro SW, Teding van Berkhout F, Kimpen JL, Wolfs TF: Diagnostic value of serological tests against Pseudomonas aeruginosa in a large cystic fibrosis population. Thorax 2006, 61:689-693.
28. Aaron SD, Kottachchi D, Ferris WJ, Vandemheen KL, St Denis ML, Plouffe A, Doucette SP, Saginur R, Chan FT, Ramotar K: Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur Respir J 2004, 24:631-637.
29. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, Hiatt P, McCoy K, Castile R, Smith AL, Ramsey BW: Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2002, 183:444-452.
30. Costerton JW: Cystic fibrosis pathogenesis and the role of biofilms in persistent infection. Trends Microbiol 2001, 9:50-52.
31. Martin DW, Schurr MJ, Mudd MH, Govan JR, Holloway BW, Deretic BW: Mechanism of conversion to mucoid in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Nat Acad Sci USA 1993, 90:8377-8381.
32. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infects Dis 1996, 23:532-537.
33. Wallet F, Perez T, Armand S, Wallaert B, Courcol RJ: Pneumonia Due to Bordetella bronchiseptica in a Cystic Fibrosis Patient: 16S rRNA Sequencing for Diagnosis Confirmation. J Clin Microbiol 2002, 40:2300-2301.
34. Ner Z, Ross LA, Horn MV, Keens TG, MacLaughlin EF, Starnes VA, Woo MS: Bordetella bronchiseptica infection in pediatric lung transplant recipients. Pediatr Transplantation 2003, 7:413-417.
35. Melo-Coutinho HD: Burkholderia cepacia complex: Virulence characteristics, importance and relationship with cystic fibrosis. Indian J Med Sci 2007, 61:422-429.
36. LiPuma JJ, Dulaney BJ, McMenamin JD, Whitby PW, Stull TL, Coenye T, Vandamme P: Development of rRNA-based PCR assays for indentification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999, 37:3167-3170.
37. Soni R, Marks G, Henry DA, Robinson M, Moriarty C, Parsons S, Taylor P, Mahenthiralingam E, Speert DP, Bye PT: Effect of Burkholderia cepacia infection in the clinical course of patients with cystic fibrosis: A pilot study in a Sydney clinic. Respirology 2002, 7:241-245.
38. Vermis K, Coenye T, Lipuma JJ, Mahenthiralingam E, Nelis HJ, Vandamme P: Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol 2004, 54:689-691.
39. Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B, Speert DP: Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: Virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001, 33:1469-1475.
40. Kennedy MP, Coakley RD, Donaldson SH, Aris RM, Hohneker K, Wedd JP, Knowles MR, Gilligan PH, Yankaskas JR: Burkholderia gladioli: Five year experience in a cystic fibrosis and lung transplantation center. J Cyst Fibros 2007, 6:267-273.
41. O'Carroll M, Kidd T, Coulter C, Smith H, Rose B, Harbour C, Bell S: Burkholderia pseudomallei: Another emerging pathogen in cystic fibrosis. Thorax 2003, 58:1087-1091.
42. Barth AL, Abreu e Silva FA, Hoffmann Vieira M, Zavascki P, Ferreira PAC, Cunha LG Jr.,3, Albano RA, Marques EA: Cystic Fibrosis patient with Burkholderia pseudomallei infection acquired in Brazil. J Clin Microbioly 2007, 45:4077-4080.
43. Miller MB, Gilligan PH: Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J Clin Microbiol 2003, 41:4009-4015.
44. Liu L, Coenye T, Burns JL, Whitby PW, Stull TL, LiPuma JJ: Ribosomal DNA-Directed PCR for Identification of Achromobacter (Alcaligenes) xylosoxidans Recovered from Sputum Samples from Cystic Fibrosis Patients. J Clin Microbiol 2002, 40:1210-1213.
45. Tan K, Conway SP, Brownlee KG, Etherington C, Peckham DG: Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002, 34:101-104.
46. Van Daele S, Verhelst R, Claeys G, Verschraegen G, Franckx H, Van Simaey L, de Ganck C, De Baets F, Vaneechoutte M: Shared Genotypes of Achromobacter xylosoxidans Strains Isolated from Patients at a Cystic Fibrosis Rehabilitation Center. J Clin Microbiol 2005, 43:2998-3002.
47. Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ: Characterization of Unusual Bacteria Isolated from Respiratory Secretions of Cystic Fibrosis Patients and Description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 2002, 40:2062-2069.
48. Chiron R, Marchandin H, Counil F, Jumas-Bilak E, Freydière AM, Bellon G, Husson MO, Turck D, Brémont F, Chabanon G, Segonds C: Clinical and Microbiological Features of Inquilinus sp. Isolates from Five Patients with Cystic Fibrosis. J Clin Microbiol 2005, 43:3938-3943.
49. Wellinghausen N, Essig A, Sommerburg O: Inquilinus limosus in patients with cystic fibrosis, Germany. Emerg Infect Dis 2005, 11:3390-3397.
50. Yabuuchi E, Kosako Y, Yano I, Hotta H, Nishiuchi Y: Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. nov.: Proposal of Ralstonia pickettii (Ralston, Palleroni and Doudouroff 1973) comb. nov., Ralstonia solanacearum (Smith 1896) comb. nov. and Ralstonia eutropha (Davis 1969) comb. nov. Microbiol Immunol 1995, 39:897-904.
51. Coenye T, Vandamme P, Lipuma JJ: Characterisation of unusual bacteria isolated from CF sputum. Pediatr Pulmonol 2001, 22:297.
52. Coenye T, Vandamme P, Lipuma JJ: Infection by Ralstonia Species in Cystic Fibrosis Patients: Identification of R. pickettii and R. mannitolilytica by Polymerase Chain Reaction. Emerg Infect Dis 2002, 8:692-696.
53. Burns JL, Emerson J, Stapp JR, Yim DL, Krzewinski J, Louden L, Ramsey BW, Clausen CR: Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998, 27:158-163.
54. Ferroni A, Sermet-Gaudelus I, Abachin E, Quesne G, Lenoir G, Berche P, Gaillard JL: Use of 16S rRNA gene sequencing for identification of nonfermenting Gram-negative bacilli recovered from patients attending a single cystic fibrosis center. J Clin Microbiol 2002, 40:3793-3797.
55. Coenye T, Falsen E, Hoste B, Ohlén M, Goris J, Govan JR, Gillis M, Vandamme P: Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov., and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol 2000, 50:887-99.
56. Jorgensen IM, Johansen HK, Frederiksen B, Pressler T, Hansen A, Vandamme P, Høiby N, Koch C: Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients. Pediatr Pulmonol 2003, 36:439-446.
57. Atkinson RM, Lipuma JJ, Rosenbluth DB, Dunne WM Jr: Chronic Colonization with Pandoraea apista in Cystic Fibrosis Patients Determined by Repetitive-Element-Sequence PCR. J Clin Microbiol 2006, 44:833-8336.
58. Renders N, Verbrugh H, van Belkum A: Dynamics of bacterial colonization in the respiratory tract of patients with cystic fibrosis. Infect Genet Evol 2001, 1:29-39.
59. del Campo R, Morosini MI, de la Pedrosa EG, Fenoll A, Muñoz-Almagro C, Máiz L, Baquero F, Cantón R: Population Structure, Antimicrobial Resistance, and Mutation Frequencies of Streptococcus pneumoniae Isolates from Cystic Fibrosis Patients. J Clin Microbiol 2005, 43:2207-2214.
60. Munõz C, Juncosa T, Gené A, Fortea J, Séculi JL, Latorre C: Microbiological study of the respiratory tract in children with cystic fibrosis. Enferm Infecc Microbiol Clin 1996, 14:142-144.
61. Denton M, Kerr KG: Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol 1998, 11:57-80.
62. Goss CH, Otto K, Aitken ML, Rubenfeld GD: Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356-361.
63. Goss CH, Mayer-Hamblett N, Aitken ML, Rubenfeld GD, Ramsey BW: Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax 2004, 59:955-959.
64. Bauernfeind A, Emminger G, Horl G, Ott S, Przyklenk B, Weisslein-Pfister C: Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis. Infection 1987, 15:403-406.
65. Peltroche-Llacsahuanga H, Haase G, Kentrup H: Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998, 17:132-134.
66. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M: Achromobacter xylosoxidans in cystic fibrosis: Prevalence and clinical relevance. J Cyst Fibros 2007, 6:75-78.
67. Magalhães M, Britto MCA, Bezerra PGM, Veras A: Prevalence of potentially pathogenic bacteria in respiratory specimens of cystic fibrosis patients from Recife. J Bras Patol Med Lab 2004, 40:223-227.
68. Román F, Cantón R, Pérez-Vázquez M, Baquero F, Campos J: Dynamics of Long-Term Colonization of Respiratory Tract by Haemophilus influenzae in Cystic Fibrosis Patients Shows a Marked Increase in Hypermutable Strains. J Clin Microbiol 2004, 42:1450-1459.
69. Ledson MJ, Gallagher MJ, Corkill JE, Hart CA, Walshaw MJ: Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia. Thorax 1998, 53:432-436.
70. Li Z, Kosorok MR, Farrell PM: Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005, 293:581-588.
71. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB: Pulmonary outcome in cystic fibrosis is influenced primarily bymucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999, 67:4744-4750.
72. Mulheran M, Degg C, Burr S, Morgan DW, Stableforth DE: Occurrence and Risk of Cochleotoxicity in Cystic Fibrosis Patients Receiving Repeated High-Dose Aminoglycoside Therapy. Antimicrob Agents Chemother 2001, 9:2502-2509.
73. Coenye T, Lipuma JJ: Multilocus restriction typing: A novel tool for studying global epidemiology of Burkholderia cepacia complex infection in cystic fibrosis. J Infect Dis 2002, 185:1454-1462.
74. Blumer JL, Saiman L, Konstan MW, Melnick D: The Efficacy and Safety of Meropenem and Tobramycin vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis. Chest 2005, 128:2336-2346.
75. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T: Once-daily tobramycin in cystic fibrosis: Better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother 2006, 58:822-829.
76. Marier JF, Brazier JL, Lavigne J, Ducharme MP: Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: A pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats. J Antimicrob Chemother 2003, 52:247-252.
77. Dong HK, Chung-Dar L: Polyamines Increase Antibiotic Susceptibility in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:1623-1627.
78. Wagner T, Soong G, Sokol S, Saiman L, Prince A: Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients. Chest 2005, 128:912-919.
79. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A: Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. Eur Respir J 2000, 16:749-767.
80. Ho AS, Lee TWR, Denton M, Conway SP, Brownlee KG: Regimens for eradicating early Pseudomonas aeruginosa infection in children do not promote antibiotic resistance in this organism. J Cyst Fibros in press. doi:10.1016/j.jcf.2008.08.001
81. Pitt TL, Sparrow M, Warner M, Stefanidou M: Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents. Thorax 2003, 58:794-796.
82. Zhang L, Parente J, Harris SM: Antimicrobial Peptide Therapeutics for Cystic Fibrosis. Antimicrob Agents Chemother 2005, 49:2921-2927.
83. Etienne O, Picart C, Taddei C, Haikel Y, Dimarcq JL, Schaaf P, Voegel JC, Ogier JA, Egles C: Multilayer Polyelectrolyte Films Functionalized by Insertion of Defensin: A New Approach to Protection of Implants from Bacterial Colonization. Antimicrob Agents Chemother 2004, 48:3662-3669.
84. Ratjen F, Doring G: Cystic fibrosis. Lancet 2003, 361:681-689.
85. Gibson RL, Burns JL, Ramsey BW: Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.